Drugs

Papers
(The TQCC of Drugs is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Prevention and Treatment of Monkeypox313
BNT162b2 mRNA COVID-19 Vaccine: First Approval224
Pharmaco-Immunomodulatory Therapy in COVID-19191
Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences174
Inclisiran: First Approval170
Lumasiran: First Approval167
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin167
Remdesivir: First Approval166
The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update164
Nirmatrelvir Plus Ritonavir: First Approval156
Casimersen: First Approval135
Sacituzumab Govitecan: First Approval134
Pemigatinib: First Approval127
Aducanumab: First Approval114
Viltolarsen: First Approval114
Sotorasib: First Approval112
Risdiplam: First Approval99
Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update92
New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma92
Acute Pancreatitis: Diagnosis and Treatment92
Setmelanotide: First Approval91
TRPV1-Targeted Drugs in Development for Human Pain Conditions91
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile I90
Managing Diabetic Foot Ulcers: Pharmacotherapy for Wound Healing88
Selpercatinib: First Approval86
Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis85
Bulevirtide: First Approval84
Belantamab Mafodotin: First Approval83
Remimazolam: First Approval83
Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?83
Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects80
Pharmacokinetics and Pharmacodynamics of Posaconazole79
Orelabrutinib: First Approval79
Inhaled Liposomal Antimicrobial Delivery in Lung Infections73
New and Emerging Systemic Treatments for Atopic Dermatitis72
Ozanimod: First Approval72
Nivolumab Plus Relatlimab: First Approval72
Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer71
Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review69
REGN-EB3: First Approval68
Selumetinib: First Approval67
Tirabrutinib: First Approval67
ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3–5: A Network Meta-Analysis of Randomised Clinical Trials66
Fabry Disease: The Current Treatment Landscape66
Lonafarnib: First Approval66
Amivantamab: First Approval65
Pralsetinib: First Approval63
Capmatinib: First Approval62
Decitabine/Cedazuridine: First Approval62
HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety61
Belzutifan: First Approval60
Inebilizumab: First Approval60
Savolitinib: First Approval60
MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-1958
Bempedoic Acid: First Approval57
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations56
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder56
Remimazolam: A Review in Procedural Sedation56
Deucravacitinib: First Approval55
Faricimab: First Approval54
Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review54
Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma53
Molnupiravir: First Approval52
Nintedanib: A Review in Fibrotic Interstitial Lung Diseases51
Casirivimab/Imdevimab: First Approval51
Tepotinib: First Approval51
Tisotumab Vedotin: First Approval50
Targeting AMPK by Statins: A Potential Therapeutic Approach50
Tucatinib: First Approval49
Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections49
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma48
Disitamab Vedotin: First Approval48
Dostarlimab: First Approval48
Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation47
Abrocitinib: First Approval47
Current Status of Clinical Trials on Tau Immunotherapies46
Efgartigimod: First Approval46
Third-Generation Antiseizure Medications for Adjunctive Treatment of Focal-Onset Seizures in Adults: A Systematic Review and Network Meta-analysis46
Loncastuximab Tesirine: First Approval46
Filgotinib: First Approval45
Lurbinectedin: First Approval45
Management of Thrombotic Complications in COVID-19: An Update45
Contezolid: First Approval45
Trilaciclib: First Approval44
Vutrisiran: First Approval44
Ripretinib: First Approval44
Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer44
Telitacicept: First Approval44
The G-Quadruplex/Helicase World as a Potential Antiviral Approach Against COVID-1944
Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective44
Umbralisib: First Approval43
Odevixibat: First Approval43
Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain43
Pegcetacoplan: First Approval42
Cabotegravir Plus Rilpivirine: First Approval42
Infigratinib: First Approval42
Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations42
Daprodustat: First Approval42
Naxitamab: First Approval41
The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review41
Tirzepatide: First Approval41
Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections40
Therapeutic Options in Hereditary Optic Neuropathies40
Isatuximab: First Approval40
Envafolimab: First Approval40
Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma39
Lecanemab: First Approval39
Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder39
Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs39
Symptomatic Efficacy of Pharmacological Treatments for Knee Osteoarthritis: A Systematic Review and a Network Meta-Analysis with a 6-Month Time Horizon38
Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics38
Rimegepant: First Approval38
Anifrolumab: First Approval38
Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals37
Satralizumab: First Approval37
Cadonilimab: First Approval37
Regdanvimab: First Approval37
Givosiran: A Review in Acute Hepatic Porphyria37
Voclosporin: First Approval36
Tebentafusp: First Approval36
Lazertinib: First Approval36
Tezepelumab: First Approval36
Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents36
Ocrelizumab: A Review in Multiple Sclerosis36
Functional Dyspepsia: Diagnostic and Therapeutic Approaches35
Eptinezumab: First Approval35
Evinacumab: First Approval35
Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review35
Chronic Pancreatitis: Epidemiology, Diagnosis, and Management Updates35
Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists35
Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?34
Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy34
Melphalan Flufenamide (Melflufen): First Approval34
Vadadustat: First Approval33
Sotrovimab: First Approval33
Fuzuloparib: First Approval33
Daridorexant: First Approval33
Mavacamten: First Approval33
Tremelimumab: First Approval33
Spesolimab: First Approval32
Mosunetuzumab: First Approval32
Asciminib: First Approval32
Are New Antiretroviral Treatments Increasing the Risk of Weight Gain?32
Dupilumab: A Review in Chronic Rhinosinusitis with Nasal Polyps31
Finerenone: First Approval31
Baloxavir Marboxil: A Review in Acute Uncomplicated Influenza31
Teclistamab: First Approval31
Avacopan: First Approval31
Pamiparib: First Approval31
Tixagevimab + Cilgavimab: First Approval30
Nirsevimab: First Approval30
Oliceridine: First Approval30
Mobocertinib: First Approval30
Vericiguat: First Approval30
Olverembatinib: First Approval29
REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study29
Epidemiology, Treatments, and Vaccine Development for Antimicrobial-Resistant Neisseria gonorrhoeae: Current Strategies and Future Directions29
A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes29
Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents29
Mirvetuximab Soravtansine: First Approval29
Bruton’s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease29
Ansuvimab: First Approval28
Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics28
Difelikefalin: First Approval28
Maralixibat: First Approval28
Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections28
Belumosudil: First Approval28
Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry28
Tapinarof Cream 1%: First Approval27
Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2)27
Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A27
Atogepant: First Approval27
Uveitis Therapy: The Corticosteroid Options27
Novel Approaches Towards a Functional Cure of HIV/AIDS27
Ozoralizumab: First Approval26
Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa26
Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence26
Donafenib: First Approval26
0.03082799911499